BIIB Quote, Financials, Valuation and Earnings

Moderna has a net margin of 15.76% compared to Biogen's net margin of 0.7%. Biogen's return on equity of 10.52% beat Moderna's return on equity of -17.44%.

Biogen has a consensus price target of $242.83, signalling upside risk potential of 62.95%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of -0.081, which suggesting that the stock is 108.074% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Moderna quarterly revenues of $1.9B. Biogen's net income of $388.5M is higher than Moderna's net income of $13M. Notably, Biogen's price-to-earnings ratio is 13.46x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.26x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 15.76% compared to Biogen's net margin of 25.23%. Biogen's return on equity of 10.52% beat Pfizer's return on equity of 4.63%.

Biogen has a consensus price target of $242.83, signalling upside risk potential of 62.95%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Biogen has higher upside potential than Pfizer, analysts believe Biogen is more attractive than Pfizer.

Biogen has a beta of -0.081, which suggesting that the stock is 108.074% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Biogen pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are smaller than Pfizer quarterly revenues of $17.7B. Biogen's net income of $388.5M is lower than Pfizer's net income of $4.5B. Notably, Biogen's price-to-earnings ratio is 13.46x while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.26x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 15.76% compared to Biogen's net margin of 36.03%. Biogen's return on equity of 10.52% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Biogen has a consensus price target of $242.83, signalling upside risk potential of 62.95%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.39%. Given that Biogen has higher upside potential than Regeneron Pharmaceuticals, analysts believe Biogen is more attractive than Regeneron Pharmaceuticals.

Biogen has a beta of -0.081, which suggesting that the stock is 108.074% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Biogen's net income of $388.5M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Biogen's price-to-earnings ratio is 13.46x while Regeneron Pharmaceuticals's PE ratio is 17.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.26x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 15.76% compared to Biogen's net margin of -788.06%. Biogen's return on equity of 10.52% beat Sage Therapeutics's return on equity of -48.2%.

Biogen has a consensus price target of $242.83, signalling upside risk potential of 62.95%. On the other hand Sage Therapeutics has an analysts' consensus of $24.39 which suggests that it could grow by 64.23%. Given that Sage Therapeutics has higher upside potential than Biogen, analysts believe Sage Therapeutics is more attractive than Biogen.

Biogen has a beta of -0.081, which suggesting that the stock is 108.074% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.067%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Biogen's net income of $388.5M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Biogen's price-to-earnings ratio is 13.46x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 2.26x versus 3.11x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.